Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience

Nivolumab is an effective and safe treatment in HCC.

Detalles Bibliográficos
Autores principales: Al jarroudi, Ouissam, Chaabouni, Hamed, Ulusakarya, Ayhan, Almohamad, Wathek, Gumus, Yusuf, Goldschmidt, Emma, Afqir, Said, Morère, Jean‐francois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077298/
https://www.ncbi.nlm.nih.gov/pubmed/33936657
http://dx.doi.org/10.1002/ccr3.3970
_version_ 1783684854309715968
author Al jarroudi, Ouissam
Chaabouni, Hamed
Ulusakarya, Ayhan
Almohamad, Wathek
Gumus, Yusuf
Goldschmidt, Emma
Afqir, Said
Morère, Jean‐francois
author_facet Al jarroudi, Ouissam
Chaabouni, Hamed
Ulusakarya, Ayhan
Almohamad, Wathek
Gumus, Yusuf
Goldschmidt, Emma
Afqir, Said
Morère, Jean‐francois
author_sort Al jarroudi, Ouissam
collection PubMed
description Nivolumab is an effective and safe treatment in HCC.
format Online
Article
Text
id pubmed-8077298
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80772982021-04-29 Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience Al jarroudi, Ouissam Chaabouni, Hamed Ulusakarya, Ayhan Almohamad, Wathek Gumus, Yusuf Goldschmidt, Emma Afqir, Said Morère, Jean‐francois Clin Case Rep Case Reports Nivolumab is an effective and safe treatment in HCC. John Wiley and Sons Inc. 2021-02-20 /pmc/articles/PMC8077298/ /pubmed/33936657 http://dx.doi.org/10.1002/ccr3.3970 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Al jarroudi, Ouissam
Chaabouni, Hamed
Ulusakarya, Ayhan
Almohamad, Wathek
Gumus, Yusuf
Goldschmidt, Emma
Afqir, Said
Morère, Jean‐francois
Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience
title Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience
title_full Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience
title_fullStr Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience
title_full_unstemmed Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience
title_short Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience
title_sort anti‐programmed death‐1 therapy in advanced hepatocellular carcinoma: a real‐world experience
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077298/
https://www.ncbi.nlm.nih.gov/pubmed/33936657
http://dx.doi.org/10.1002/ccr3.3970
work_keys_str_mv AT aljarroudiouissam antiprogrammeddeath1therapyinadvancedhepatocellularcarcinomaarealworldexperience
AT chaabounihamed antiprogrammeddeath1therapyinadvancedhepatocellularcarcinomaarealworldexperience
AT ulusakaryaayhan antiprogrammeddeath1therapyinadvancedhepatocellularcarcinomaarealworldexperience
AT almohamadwathek antiprogrammeddeath1therapyinadvancedhepatocellularcarcinomaarealworldexperience
AT gumusyusuf antiprogrammeddeath1therapyinadvancedhepatocellularcarcinomaarealworldexperience
AT goldschmidtemma antiprogrammeddeath1therapyinadvancedhepatocellularcarcinomaarealworldexperience
AT afqirsaid antiprogrammeddeath1therapyinadvancedhepatocellularcarcinomaarealworldexperience
AT morerejeanfrancois antiprogrammeddeath1therapyinadvancedhepatocellularcarcinomaarealworldexperience

Ejemplares similares